Startups
2018
REMAB THERAPEUTICS SLRemoving Antibodies for Health Solutions
Provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
Provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
Address
Universitat Autònoma de Barcelona, Avinguda de Can Domènech s/n, 08193 Cerdanyola del Vallès, Spain
CERCA ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
CERCA Center Contact
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Disruptive strategy to elicit protective immunity against Multidrug-resistant (MDR) Gram-negative bacteria
RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
RemAb is developing a pipeline with different indications. Our most advanced program aims to provide immediate protection to patients admitted to Intensive Care Units (ICU) without generating antimicrobial resistance (AMR).
Product description
RA01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.